What Is Semax? A Research Overview of the ACTH(4-10) Analog Nootropic Peptide

Semax peptide ACTH(4-10) analog nootropic research Durham Peptides Canada

Semax occupies a distinct corner of the peptide research field — a heptapeptide developed in Russia for cognitive and neuroprotective research, with mechanisms centered on BDNF (brain-derived neurotrophic factor) modulation rather than the receptor-binding

mechanisms that characterize most other peptide categories. Unlike most peptides commonly discussed in the Canadian research peptide market, Semax has decades of Russian pharmaceutical research history alongside its presence as a research-use peptide. For Canadian researchers entering nootropic peptide research, Semax represents one of the better-characterized compounds in this distinct research category.

This article provides a research-focused overview of Semax — its development at the Russian Academy of Sciences, the ACTH(4-10) origins that define its structure, the BDNF-related research mechanism, the published research literature, and the Canadian regulatory context.

Semax is now available in the Durham Peptides catalog as Semax 10mg.

For the broader nootropic peptide context, see Nootropic Peptides Research Overview.

The Origin: Russian Academy of Sciences and ACTH Research

Semax's research history begins at the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow, where researchers in the late 1980s and early 1990s investigated synthetic analogs of adrenocorticotropic hormone (ACTH).

ACTH is a 39-amino-acid peptide produced by the pituitary gland with primary roles in regulating adrenal steroid hormone production. But research had identified that specific fragments of ACTH retained certain biological activities independent of the full hormone's adrenal effects. The fragment ACTH(4-10) — corresponding to amino acids 4 through 10 of the full ACTH sequence — had been studied for cognitive and behavioral effects in both human and animal research, though native ACTH(4-10) was rapidly degraded by enzymatic processes.

The Russian researchers modified ACTH(4-10) by adding a Pro-Gly-Pro tripeptide extension to the C-terminus. This modification — the same Pro-Gly-Pro sequence that appears at the C-terminus of various stable peptides — provides resistance to enzymatic degradation, extending the practical research half-life of the compound. The resulting heptapeptide became known as Semax.

Semax Structure

Semax consists of seven amino acids in sequence:

Met-Glu-His-Phe-Pro-Gly-Pro

The structural breakdown:

• Met-Glu-His-Phe — the first four residues correspond to ACTH(4-7), the active region from the original ACTH research

• Pro-Gly-Pro — the C-terminal tripeptide extension that provides enzymatic stability

The molecular weight is approximately 813 daltons — a relatively small peptide compared to many research compounds. The small size has practical implications for tissue penetration, blood-brain barrier considerations (relevant for nootropic research), and intranasal administration that has been explored in published research.

Semax is produced via Solid-Phase Peptide Synthesis (SPPS) using synthetic amino acids — the modern manufacturing standard. The relatively simple seven-amino-acid structure makes manufacturing straightforward compared to longer modified peptides. See Peptide Manufacturing 101: How Research Peptides Are Made From Amino Acids to Vial.

The Research Mechanism: BDNF Modulation

The published research literature has investigated Semax's mechanism extensively, with several major findings:

BDNF (Brain-Derived Neurotrophic Factor) modulation. This is the central mechanism documented in published research. A landmark 2006 study by Dolotov and colleagues demonstrated that a single application of Semax (50 μg/kg) results in approximately 1.4-fold increase in BDNF protein levels in the rat hippocampus, accompanied by 1.6-fold increase in TrkB tyrosine phosphorylation, and approximately 3-fold increase in BDNF mRNA expression. BDNF is a protein critical for synaptic plasticity, neuronal growth, and cognitive function — making BDNF-modulating compounds particularly interesting for cognitive and neuroprotective research.

Dopaminergic and serotonergic system effects. Published research has documented Semax's activation of dopaminergic and serotonergic brain systems in rodent models, with effects on neurotransmitter metabolism observable within 30 minutes to several hours after administration.

Neuroprotective effects in cerebral ischemia models. Multiple published studies have examined Semax in cerebral ischemia (stroke) research models, with documented protective effects on infarct size and neurological outcomes in research populations.

Independence from melanocortin receptor activity. Despite being derived from ACTH (which engages melanocortin receptors for its primary biological effects), Semax's nootropic and neuroprotective effects appear to operate through different mechanisms. The compound is not generally classified as a melanocortin receptor agonist for its primary research applications.

Pharmacokinetic considerations. Semax has been studied extensively in intranasal administration formulations in research populations — the small size and stability characteristics support this route of administration, which provides direct nervous system access while avoiding gastrointestinal degradation.

For pharmacokinetic context, see Peptide Half-Life Explained: Why Some Peptides Last Hours and Others Days.

The Russian Pharmaceutical History

Semax has an unusually thorough pharmaceutical research history compared to most research peptides — but with an important geographic distinction.

In Russia, Semax has been registered as a pharmaceutical product for specific approved indications, dispensed through Russian pharmaceutical channels for use in clinical research and certain medical applications within the Russian regulatory framework. The compound has been the subject of substantial Russian-language clinical research that doesn't always appear prominently in English-language Western research databases.

Important context for Canadian researchers: Russian pharmaceutical approval is entirely separate from Health Canada approval, FDA approval, or EU regulatory approval. Semax has not received approval as a pharmaceutical product in Canada, the United States, or the European Union. The Russian regulatory pathway is its own framework that doesn't translate directly to other jurisdictions.

For Canadian research peptide work, this means:

• The Russian research base provides substantive published literature on Semax's pharmacology

• The Russian pharmaceutical regulatory status does not constitute approval in Canada

• Semax operates in Canada under the standard research peptide framework — sold for laboratory and research applications under research-use-only framing

• Health Canada has not approved Semax for any therapeutic indication

For the broader Canadian regulatory framework, see Are Peptides Legal in Canada? A Complete Guide to Research Peptide Laws.

The Nootropic Peptide Category

Semax sits within a broader research category of nootropic peptides — synthetic peptides studied for cognitive and neuroprotective effects. The category includes:

Semax. The compound covered in this article. ACTH(4-10) analog with Pro-Gly-Pro extension.

Selank. Another Russian-origin neuropeptide with anxiolytic and neuroprotective research applications. Sometimes used in combination with Semax in research protocols. Not currently in the Durham Peptides catalog.

P21. A research peptide derived from CNTF (ciliary neurotrophic factor). Not currently in the Durham Peptides catalog.

Other ACTH-related research peptides. The broader ACTH research literature includes various other fragments and analogs.

For complete coverage of the broader category, see Nootropic Peptides Research Overview.

How Semax Differs from Other Research Peptide Categories

Semax occupies a distinct corner of the peptide research field:

Different from melanocortin peptides. Despite ACTH origins, Semax doesn't operate primarily through melanocortin receptors for its nootropic effects. Different from PT-141 which is melanocortin-receptor-active.

Different from metabolic peptides. Semaglutide, tirzepatide, and retatrutide work through incretin receptors. Semax's mechanism is in the central nervous system through BDNF modulation.

Different from tissue-repair peptides. BPC-157 and TB-500 work through tissue-localized angiogenic and cell migration pathways. Semax's research focus is in central nervous system biology.

Different from anti-aging peptides. GHK-Cu and MOTS-c work through gene expression modulation and mitochondrial pathways respectively. Different mechanism families.

Different from growth hormone peptides. Tesamorelin and other GHRH analogs work through the hypothalamic-pituitary GH axis. Semax's research focus is on neurotrophic factors rather than GH biology.

Manufacturing and Quality Considerations

For Semax, the standard research peptide quality framework applies:

Identity verification. Mass spectrometry should confirm the molecular weight matches Semax's expected value (approximately 813 Da). The relatively simple seven-amino-acid structure makes identity confirmation straightforward. See How to Read a Janoshik COA: HPLC, Mass Spec, and the Unique Key Explained.

Purity verification. ≥99% HPLC purity is the research-grade standard. See Peptide Purity: Why 99% Matters.

Third-party verification. Independent COA via Janoshik Analytical. For Durham Peptides Semax 10mg, the COA is at durhampeptides.ca/lab-results.

Storage. Standard research peptide storage framework — refrigerated or frozen lyophilized form, refrigerated reconstituted form. See Peptide Storage & Shelf Life.

Reconstitution. Standard practices apply. See How to Reconstitute Peptides and Peptide Reconstitution Calculator Guide.

Frequently Asked Questions

What is Semax? A heptapeptide (seven-amino-acid) synthetic peptide consisting of the first four amino acids of ACTH(4-10) plus a Pro-Gly-Pro extension. Developed at the Russian Academy of Sciences. Studied extensively in published research literature for BDNF modulation, neuroprotective effects, and cognitive research applications.

What does Semax stand for? "Semax" is the proprietary research name given to the compound by its Russian developers. The name doesn't expand into an acronym but functions as the specific identifier for this particular ACTH(4-10) analog with the Pro-Gly-Pro extension.

Is Semax FDA-approved? No. Semax has not received FDA approval. It is sold under research-use-only framing for laboratory and research applications.

Is Semax approved by Health Canada? No. Semax has not received Health Canada approval. It operates under the standard research peptide framework — research-use-only for laboratory and research applications.

Is Semax approved in Russia? Semax has been registered as a pharmaceutical product in Russia for specific approved indications under the Russian regulatory framework. This Russian approval is entirely separate from Health Canada or FDA approval and does not constitute approval in any other jurisdiction.

Does Durham Peptides sell Semax? Yes. Semax 10mg is now available with full Janoshik third-party testing and Canadian-domestic shipping.

What's Semax's research mechanism? The published research literature has documented Semax's effects on BDNF (brain-derived neurotrophic factor) modulation, TrkB receptor activation, dopaminergic and serotonergic system effects, and neuroprotective effects in cerebral ischemia models. The central mechanism appears to operate through BDNF and related neurotrophic signaling rather than direct receptor agonism.

How is Semax related to ACTH? Semax is derived from amino acids 4-10 of adrenocorticotropic hormone (ACTH) plus a Pro-Gly-Pro extension. The first four amino acids correspond to ACTH(4-7). However, Semax's research mechanisms appear to operate through BDNF modulation rather than primary ACTH-related adrenal effects.

Can Semax be administered intranasally? Published research has examined Semax in intranasal administration formulations. The small molecular size and stability characteristics support this research approach. Whether intranasal administration is appropriate for any specific research protocol depends on the research design.

Is Semax a nootropic peptide? Yes — Semax is one of the most-studied compounds in the nootropic peptide research category. The published research has examined cognitive, neuroprotective, and BDNF-related effects in research populations. See Nootropic Peptides Research Overview.

How is Semax manufactured? Solid-Phase Peptide Synthesis (SPPS) using synthetic amino acids — the modern standard for research peptide manufacturing. The relatively simple seven-amino-acid structure makes manufacturing straightforward.

Is Semax vegan? Yes. Modern Semax is manufactured via SPPS with synthetic amino acids — no animal-derived materials. See Vegan Peptides.

Final Thoughts

Semax represents a distinctive research peptide category — the Russian-origin nootropic peptides with substantial published research on cognitive and neuroprotective

mechanisms. The combination of decades of Russian pharmaceutical research history plus continued research peptide presence makes Semax one of the better-documented compounds in nootropic peptide research, though the geographic origin of much of the research means English-language familiarity has been slower to develop than for some other peptide categories.

For Canadian researchers, Semax is now available through Durham Peptides as Semax 10mg — manufactured via Solid-Phase Peptide Synthesis, third-party tested by Janoshik Analytical, and sold with the same research-use-only framework that applies to the entire catalog.

For continued reading, see Nootropic Peptides Research Overview, What Is PT-141?, The Complete Peptide Glossary, and Peptide Research Trends 2026.

Browse the complete Durham Peptides catalog at durhampeptides.ca/category/all-products. View all Janoshik-verified COAs at durhampeptides.ca/lab-results.

Selected Research References

1. Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an Analog of ACTH(4-10) with Cognitive Effects, Regulates BDNF and trkB Expression in the Rat Hippocampus. Brain Research. 2006;1117(1):54-60. https://pubmed.ncbi.nlm.nih.gov/16996037/

2. Dolotov OV, Karpenko EA, Seredenina TS, et al. Semax, an Analogue of Adrenocorticotropin (4-10), Binds Specifically and Increases Levels of Brain-Derived Neurotrophic Factor Protein in Rat Basal Forebrain. Journal of Neurochemistry. 2006;97(Suppl 1):82-86. https://pubmed.ncbi.nlm.nih.gov/16635254/

3. Eremin KO, Kudrin VS, Saransaari P, et al. Semax, an ACTH(4-10) Analogue with Nootropic Properties, Activates Dopaminergic and Serotoninergic Brain Systems in Rodents. Neurochemical Research. 2005;30(12):1493-1500. https://pubmed.ncbi.nlm.nih.gov/16362768/

4. Ashmarin IP, Nezavibatko VN, Levitskaya NG, Koshelev VB, Kamensky AA. Design and Investigation of an ACTH(4-10) Analogue Lacking D-Amino Acids and Hydrophobic Radicals. Neuroscience Research Communications. 1995;16(2):105-112. Background reference on Semax development.

5. Romanova GA, Silachev DN, Shakova FM, et al. Neuroprotective and Antiamnestic Effects of Semax during Experimental Ischemic Infarction of the Cerebral Cortex. Bulletin of Experimental Biology and Medicine. 2006;142(6):663-666. https://pubmed.ncbi.nlm.nih.gov/17603667/

6. Agapova TY, Agniullin YV, Shadrina MI, et al. Neurotrophin Gene Expression in Rat Brain under the Action of Semax, an Analogue of ACTH 4-10. Neuroscience Letters. 2007;417(2):201-205. https://pubmed.ncbi.nlm.nih.gov/17353091/

All products sold by Durham Peptides are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease. This article is informational and does not constitute medical advice.